|
For immediate release |
26 September 2008 |
Futura Medical plc
('Futura' or 'the Group' or 'the Company')
Corporate brokership
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that Canaccord Adams, the Company's Nominated Adviser, is now the Company's sole broker. Canaccord Adams was formerly joint broker to the Company.
For any further information please contact:
|
Futura Medical plc |
|
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
mail to: [email protected] |
|
|
Canaccord Adams |
|
|
Ryan Gaffney / Adria Da Breo Richards |
Tel: +44 (0) 20 7050 6500 |
|
For media enquiries please contact: |
|
|
Buchanan Communications |
|
|
Mark Court / Rebecca Skye Dietrich |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock
Exchange.
www.futuramedical.co.uk
This information is provided by RNS